Diabetes management technology has advanced more dramatically in the past five years than in the previous two decades. The gap between optimal diabetes control achievable in clinical trials and that achieved in real-world clinical practice has historically been vast — technology is narrowing this gap by removing the cognitive burden of diabetes self-management that leads to decision fatigue and suboptimal choices. The diabetes supply landscape has evolved correspondingly, with CGM sensors, insulin pump consumables, and digital health integration becoming central to comprehensive diabetes care. Our diagnostic equipment section and pharmacy supplies support clinical diabetes programs.
Continuous Glucose Monitoring: The New Standard
Factory-calibrated CGM systems (Abbott FreeStyle Libre 3, Dexcom G7, Medtronic Guardian 4) provide interstitial glucose readings every 1–5 minutes with 10–14 day sensor wear — eliminating most fingerstick testing while providing time-in-range (TIR) data unavailable from HbA1c or fingerstick alone. TIR (percent of time glucose 70–180 mg/dL) is now an endorsed clinical endpoint in FDA guidance and endorsed by the ADA — replacing HbA1c as the primary metric in CGM-using patients. CGM use in type 1 diabetes: three landmark RCTs found CGM use reduces HbA1c by 0.5–0.9% and significantly increases TIR vs fingerstick monitoring. In type 2 diabetes: DIAMOND and MOBILE RCTs showed comparable CGM benefits in non-insulin-using type 2 patients — a population where CGM adoption has lagged but is growing rapidly with Medicare coverage expansion. CGM sensors and monitoring supplies are available through our diagnostic equipment catalog.
Automated Insulin Delivery (Closed-Loop Systems)
Hybrid closed-loop systems — combining CGM, insulin pump, and control algorithm that automatically adjusts basal insulin delivery based on real-time glucose — have achieved outcomes in RCTs that exceed anything achievable with conventional insulin therapy. The JDRF iDCL trial showing the Tandem Control-IQ system achieving 74% TIR (vs 59% in standard pump group) over 6 months in type 1 diabetes is the benchmark study. The Omnipod 5 tubeless system, MiniMed 780G, and Tandem Control-IQ all have FDA clearance and published RCT evidence. Closed-loop algorithm performance continues to improve — the latest MiniMed 780G achieved 79% TIR in the APET trial, approaching the >70% TIR guideline target achievable at a population level for the first time.
